Opinion|Videos|June 18, 2024
Navigating Therapy Approval for Early Breast Cancer: An Operational Perspective
Medical experts discuss their perspectives on therapy approval and the significance of formulary inclusion, emphasizing the need to carefully consider both toxicities and benefits, which may ultimately lead to the operationalization of a drug in clinical practice.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
How will the potential approval of ribociclib for early breast cancer change your treatment paradigms?
Advertisement
Related to this article
October’s oncology coverage highlighted new treatment options in rectal, breast, and prostate cancers, alongside longer-term survival findings and concerns about reduced-frequency immunotherapy.
ESMO 2026 breast cancer updates show ribociclib boosts survival, while immunotherapy and extended endocrine therapy improve end points without longer overall survival.
In an interview with Pharmacy Times, Danielle Roman, PharmD, BCOP, FHOPA, discusses NCCN breast cancer guideline updates involving ESR1 mutation testing, targeted therapies, and pharmacists’ roles in monitoring, patient counseling, and treatment access.
Specialty pharmacy liaisons improve breast cancer care by easing access barriers, managing side effects, boosting adherence, and navigating new therapies and policies.
Six-year NATALEE data show adjuvant ribociclib (Kisqali) plus endocrine therapy improves overall survival in high-risk HR+/HER2- early breast cancer, with pharmacist-led monitoring.
Pharmacists can help care for patients receiving breast cancer endocrine therapy by identifying fracture risk early and supporting appropriate bone-directed treatment throughout survivorship.
Advertisement
Advertisement
Trending on Pharmacy Times
1
October 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
2
What Happens Before the First Dose? 5 Steps That Shape Lung Cancer Treatment
3
Nicotine Vaping Linked to Lower Vascular Function in Young Adults
4
Full IDWeek Data Highlights 31-Valent Pneumococcal Conjugate Vaccine Candidate in Adults
5